Subscribe to Biological Therapies in Psychiatry -  Choose your plan >
IN THIS MONTH'S ISSUE:
March 2015

A Two-Drug Combination for Weight Loss
The new medication Contrave, which combines the opioid-receptor antagonist naltrexone (ReVia and others) with the antidepressant and smoking cessation compound bupropion (Wellbutrin, Zyban, and others), has been approved as an adjunct to diet and increased exercise for certain overweight and obese patients.

Clozapine Trumps Polypharmacy
For patients with schizophrenia, clozapine (Clozaril and others) is associated with lower costs and reduced disease-specific emergency department use.

In Brief
Brain Activity in Men and Women Differs in Response to Cigarette Smoking; Patients with Anxiety Disorders Are at Greater Risk of Hypertension than the General Population

Lack of Cataracts with Quetiapine
Despite warnings about cataracts, quetiapine (Seroquel) actually appears to have a low risk of causing cataracts.

CME Reminder
March 31, 2015 is the deadline for returning your 2014 CME posttest to earn up to 12.0 hours of category 1 credit.

A Message from Alan J. Gelenberg, M.D.

When I first started writing BTP in the 1970s, it was to bridge the gap between new knowledge in our field and its application to patient care. Over the decades since, the need for this bridge has become even greater. Neuroscience rockets forward. Psychiatrists and other clinicians have a broader array of treatments for patients with mental disorders than we even dreamed of back then. But we have less time to spend with patients and less time to keep up with developments that affect treatment decisions. Our medications, and those prescribed by colleagues in other specialties, are more varied, complex, and prone to interactions. What were formerly crisp boundaries between major psychopharmacologic categories are now murky.

This makes the modern practice of psychiatry challenging—but also fun and promising. With the expanding armamentarium of treatment options comes enhanced ability to alleviate suffering. The mission of BTP remains constant, even while the field grows. We are still here to bridge the gap, to make science applicable and relevant, and to help you in your day-to-day work relieve distress and improve function in patients' lives.